The European Academy of Dermatology and Venereology (EADV) 2026 Congress will host a late-breaking presentation supporting the use of Castle Biosciences' DecisionDx-Melanoma gene-expression profile (GEP) test in sentinel lymph node biopsy (SLNB) decision-making and risk-aligned post-surgical management of cutaneous melanoma, according to a Yahoo Finance UK report on the company's announcement.

DecisionDx-Melanoma is a 31-gene expression profile test that stratifies patients with cutaneous melanoma by recurrence and metastasis risk. The EADV 2026 late-breaking slot indicates the abstract passed the congress's peer-review process for high-impact dermatology data.

What does the test measure?

The assay evaluates the expression of 31 genes within the primary tumor and reports a result in one of four risk classes: Class 1A (lowest), Class 1B, Class 2A, and Class 2B (highest). Clinicians typically integrate the result with AJCC stage, Breslow thickness, ulceration status, and mitotic rate when deciding whether to proceed with SLNB and how intensively to follow patients after surgery.

Why does SLNB matter in melanoma staging?

Sentinel lymph node biopsy remains a standard staging procedure for melanomas with Breslow thickness generally above 0.8 mm or with high-risk features such as ulceration. A positive node upstages the patient to AJCC stage III and qualifies them for adjuvant systemic therapy, most commonly checkpoint inhibitor immunotherapy. The procedure, however, carries morbidity — including lymphedema, seroma, infection, and wound complications — and many node-negative patients derive no direct therapeutic benefit.

What does "risk-aligned post-surgical management" mean?

A risk-stratified GEP result can shape surveillance intensity, imaging cadence, and follow-up interval after wide local excision. Patients classified as low risk may follow less intensive imaging schedules, while high-risk patients typically warrant closer imaging, more frequent clinical review, and earlier referral to medical oncology. The EADV late-breaking presentation positions DecisionDx-Melanoma within this individualized care pathway.

How does the test fit into current guidelines?

The test is not a replacement for clinicopathologic staging. National Comprehensive Cancer Network (NCCN) melanoma guidelines recognize GEP tests as one of several adjunctive tools that may inform risk discussions, alongside SLNB and imaging. The EADV 2026 late-breaking data extend the peer-reviewed evidence base available to dermatologists, surgical oncologists, and medical oncologists weighing SLNB and surveillance decisions in stage I-II melanoma.

What should clinicians take from the announcement?

The late-breaking slot signals that the data cleared peer-review scrutiny for inclusion in a major European dermatology venue. Full publication of the abstract, including cohort size, study design, primary endpoints, and statistical outcomes, will determine whether the findings shift practice or simply reinforce existing patterns of test use.

Castle Biosciences has built its dermatologic oncology franchise on DecisionDx-Melanoma and a related assay, DecisionDx-SCC for cutaneous squamous cell carcinoma. The company has previously reported prospective validation studies and integration analyses with AJCC staging in peer-reviewed dermatology and oncology journals. EADV 2026 abstracts are typically released at the time of presentation; full data tables and statistical endpoints will follow thereafter.

What is the broader context?

Gene-expression profile testing in early-stage melanoma has drawn both support and skepticism. Proponents cite improved risk discrimination beyond AJCC staging alone; critics note variable test performance across cohorts and limited prospective randomized data showing survival benefit from GEP-guided management changes. The EADV 2026 late-breaking presentation enters that debate at a major European venue.

As melanoma incidence continues to rise across Europe and adjuvant therapy indications expand, GEP tests are drawing closer scrutiny from health technology assessment bodies. The EADV 2026 late-breaking data will likely feed into payer reviews, guideline updates, and dermatology practice patterns heading into 2027.